We are monitoring the impact of COVID-19 on Conjugate Vaccine Market Get in touch with us for detailed analysis Know More
Pulished Date November, 2021
ID: 12408
Share on
Share on

Global Conjugate Vaccine Market Size, Share, Trends, COVID-19 Impact & Growth Analysis Report – Segmented By Disease Indication, Type, Patient Stage, Pathogen Type & Region (North America, Europe, APAC, Latin America, Middle East and Africa) – Industry Forecast (2021 to 2026)

Pulished: November, 2021
ID: 12408
Pages: 190

Global Conjugate Vaccine Market Size (2021 to 2026)

The global conjugate vaccine market size was valued at USD 13.4 billion in 2020. Growing at a CAGR of 16.34% from 2021 to 2026, the global conjugate vaccine market is predicted to value USD 15.59 billion in 2021 and USD 33.23 billion by 2026.

A conjugate vaccination is a vaccine that uses a carrier to combine a weak antigen with a solid antigen for boost protection. Vaccines work by inducing an immune response to an antigen, which helps to prevent disease. Vaccines that contain bacterial capsule polysaccharides and are used to treat infectious diseases are known as conjugate vaccines. It boosts the polysaccharide's immunogenicity. Vaccines like this are used to protect infants and children from invasive diseases caused by bacteria, including Streptococcus pneumonia, Neisseria meningitides, H. influenzae, and Hib. For example, this technology is now being used to create conjugate vaccines for children against pneumococcal bacterial infections. Some bacteria and viruses have unique polysaccharide films that help them escape the immune system. Conjugate vaccines, which bind the unique polysaccharide coats to an organism by inducing immunity and reaction, can assist an immature immune system to recognize these microorganisms.

Impact of COVID-19 on the global conjugate vaccine market:

COVID-19 is an unprecedented global public health crisis that has impacted practically every business, with long-term consequences expected to impede industrial growth during the forecast period. Changchun Changsheng Life Sciences Limited, China's second-largest vaccine manufacturer, was held liable for falsifying its production records and was facing legal action. Examining the COVID-19 pandemic's vaccine methods and technical platforms in comparison to those utilized for prior emerging and re-emerging infectious diseases and pandemics could yield some mutually valuable lessons. Vaccine makers, regulators, health authorities, and political constituencies face significant challenges due to the tremendous scale and speed with which recent emerging infectious diseases have spread.

The coronavirus disease 2019 (COVID-19) pandemic was caused by a unique severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that devoured the entire world in less than six months, with high mortality in the elderly and those with concomitant comorbidities. Short of lockdowns, the only means of control have been a succession of imperfect and constricting mitigation techniques such as self-distancing, masking, travel limitations, and avoiding gatherings as of considering that vaccines work to prevent disease it has moderate growth during this pandemic and increased its expansion during the forecast period.

MARKET DRIVERS:

The increased use of conjugate vaccinations for adults, the rising number of regulatory approvals for conjugate vaccines, the increasing prevalence of diseases are majorly driving the global conjugate vaccines market growth.

The market is further expected to be accelerated by the rising adoption of therapeutic cancer vaccines, improved patient compliance, and expanding product pipeline, and increased efforts to adopt adequate preventive screening methods to help avoid adverse responses. With expansion initiatives to produce low-cost vaccinations and comprehensive routine vaccination programs in emerging economies, the conjugate vaccine market is predicted to increase significantly. Due to developments in research and development, the worldwide conjugate vaccine market is being driven by increased revenue from the sale of meningococcal and pneumococcal vaccines.

Rising government initiatives, together with the expanding prevalence of infectious diseases and increasing consumer awareness about disease prevention, are some of the significant factors driving the market's growth throughout the forecast period. Furthermore, technical advancements and continuous R&D initiatives for producing effective vaccines around the world are expected to give lucrative market growth opportunities. In the near future, increasing partnerships among major companies to develop and deliver vaccines for pneumococcal and meningococcal diseases in the market and ongoing clinical trial research on pneumococcal vaccines are projected to propel the global conjugated vaccines market forward. To improve immunogenicity and defend against invasive infections, conjugate vaccines combine bacterial capsular polysaccharides with a protein. They are the most efficient types of immunizations for both newborns and adults, and they are used to prevent infections in both.

MARKET RESTRAINTS:

The growth of the global conjugate vaccines market is likely to be limited by low vaccine accessibility in remote locations and the complicated production process of conjugate vaccines. In addition, the worldwide conjugate vaccination market is anticipated to be challenged by the considerable time period between the release of new conjugate vaccines in low- and high-income nations.

REPORT COVERAGE:

REPORT METRIC

DETAILS

Market Size Available

2020 to 2026

Base Year

2020

Forecast Period

2021 to 2026

Segments Covered

By Disease Indication, Type, Patient Stage, Pathogen Type & Region

Various Analyses Covered

Global, Regional & Country Level Analysis, Segment-Level Analysis, Drivers, Restraints, Opportunities, Challenges, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities

Regions Covered

North America, Europe, Asia Pacific, Latin America, Middle East & Africa

 

This research report on the global conjugate vaccine market has been segmented and sub-segmented based on disease indication, type, patient stage, pathogen type & region.

Conjugate Vaccine Market – By Type:

  • Monovalent
  • Multivalent

In the past, the monovalent conjugate vaccines sector held the most significant proportion of the market. The high quality of vaccines given by the key manufacturers and professional awareness of monovalent conjugate vaccines can be credited for the market's size. Furthermore, due to advancements in technology and government incentives, the multivalent conjugate vaccines segment is expected to be the fastest-growing segment over the forecast period.

Conjugate Vaccine Market – By Disease Indication:

  • Pneumococcal
  • Influenza
  • DTP
  • Meningococcal
  • Others

Based on the disease indication, the DTP (diphtheria-tetanus-pertussis) segment is expected to be the most lucrative segment during the forecast period. The growth of DTP is due to an increase in respiratory tract infections and their infectious nature.

Conjugate Vaccine Market – By Pathogen Type:

  • Bacterial Conjugate Vaccine
  • Viral Conjugate Vaccine
  • Combination (Viral and Bacterial) Conjugate Vaccine

Due to the high demand for treating associated disorders, the Bacterial conjugate Vaccine held most of the global conjugate vaccines market share in 2020.

Conjugate Vaccine Market – By Patient Stage:

  • Pediatrics
  • Adults

Based on the patient stage, the pediatrics conjugate vaccine has high demand and increased demand during the forecast period.

Conjugate Vaccine Market – By Region:

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

Due to increased activities by healthcare providers and hospitals, Asia Pacific is likely to fuel growth in the worldwide conjugate vaccines market. Furthermore, to meet the need, different national governments in the region are focusing on vaccination programs. For instance, the Queensland Government's National Immunization Program and India's Mission Indradhanush immunization program work to provide vaccination to children throughout their respective countries.

Due to increased initiatives by key participants in developing conjugate vaccination systems for various purposes, Europe is likely to rise at a significant rate.

The global conjugate vaccines market was dominated by North America in 2020, with the United States accounting for a large portion of the market.

KEY MARKET PARTICIPANTS:

Biological E, Bharat Biotech, Neuron Biotech, Novartis AG, Merck and Company, GlaxoSmithKline, PLC., Pfizer, Inc., Sanofi Pasteur, Serum Institute of India, Walvax Biotechnology, Royal (Wuxi) Bio-Pharmaceutical, and Zhifei Biologic are some of the noteworthy companies operating in the global conjugate vaccines market profiled in this report.

RECENT HAPPENINGS IN THIS MARKET:

  • Merck & Co, Inc. began two Phase III studies of PCV-15 (V114), an experimental polyvalent conjugate vaccination for pneumococcal disease prevention, in April 2018.
  • In 2021, in India, the Union Health Minister Manshukh Mandaviya announced the statewide rollout of the Pneumococcal Conjugate Vaccination (PCV) under the Universal Immunization Programme (UIP), claiming that the vaccine will cut child mortality by nearly 60%.
  • The US Food and Drug Administration (FDA) accepted the MenQuadfi Meningococcal Conjugate Vaccine Biologics License Application in April 2020 to prevent invasive meningococcal disease in children and adults aged two and up.
  1. Introduction                                 
    1. Market Definition                    
    2. Scope of the report                 
    3. Study Assumptions                 
    4. Base Currency, Base Year and Forecast Periods                           
  2. Research Methodology                                           
    1. Analysis Design                         
    2. Research Phases                      
      1. Secondary Research           
      2. Primary Research 
      3. Data Modelling     
      4. Expert Validation  
    3. Study Timeline                          
  3. Report Overview                                        
    1. Executive Summary                
    2. Key Inferences                       
  4. Market Dynamics                                       
    1. Impact Analysis                        
      1. Drivers      
      2. Restraints 
      3. Opportunities        
    2. Regulatory Environment                       
    3. Technology Timeline & Recent Trends                            
  5. Competitor Benchmarking Analysis                                    
    1. Key Player Benchmarking                     
      1. Market share analysis         
      2. Products/Service 
      3. Regional Presence
    2. Mergers & Acquisition Landscape                      
    3. Joint Ventures & Collaborations                        
  6. Market Segmentation                                              
    1. Global Conjugate Vaccine Market, By Type
      1. Monovalent
      2. Multivalent
      3. Market Size Estimations & Forecasts (2021-2026)   
      4. Y-o-Y Growth Rate Analysis              
      5. Market Attractiveness Index           
    2. Global Conjugate Vaccine Market, By Disease Indication
      1. Pneumococcal
      2. Influenza
      3. DTP
      4. Meningococcal
      5. Others
      6. Market Size Estimations & Forecasts (2021-2026)   
      7. Y-o-Y Growth Rate Analysis              
      8. Market Attractiveness Index         
    3. Global Conjugate Vaccine Market, By Pathogen Type
      1. Bacterial Conjugate Vaccine
      2. Viral Conjugate Vaccine
      3. Combination (Viral and Bacterial) Conjugate Vaccine
      4. Market Size Estimations & Forecasts (2021-2026)   
      5. Y-o-Y Growth Rate Analysis              
      6. Market Attractiveness Index         
    4. Global Conjugate Vaccine Market, By Patient Stage
      1. Pediatrics
      2. Adults
      3. Market Size Estimations & Forecasts (2021-2026)   
      4. Y-o-Y Growth Rate Analysis              
      5. Market Attractiveness Index         
  7. Geographical Landscape                                         
    1. Global Conjugate Vaccine Market, By Region                 
    2. North America - Market Analysis (2021 - 2026)                            
      1. By Country              
        1. USA
        2. Canada
      2. By Type    
      3. By Target 
    3. Europe                         
      1. By Country              
        1. UK
        2. France
        3. Germany
        4. Spain
        5. Italy
        6. Rest of Europe
      2. By Type    
      3. By Target 
    4. Asia Pacific                  
      1. By Country              
        1. China
        2. India
        3. Japan
        4. South Korea
        5. South East Asia
        6. Australia & NZ
        7. Rest of Asia-Pacific
      2. By Type    
      3. By Target 
    5. Latin America                            
      1. By Country              
        1. Brazil
        2. Argentina
        3. Mexico
        4. Rest of Latin America
      2. By Type    
      3. By Target 
    6. Middle East and Africa                           
      1. By Country              
        1. Middle East
        2. Africa
      2. By Type    
      3. By Target 
  8. Key Player Analysis                                    
    1. Biological E
      1. Business Description           
      2. Products/Service 
      3. Financials 
      4. SWOT Analysis      
      5. Recent Developments       
      6. Analyst Overview 
    2. Bharat Biotech
    3. Neuron Biotech
    4. Novartis AG
    5. Merck and Company
    6. GlaxoSmithKline, PLC.
    7. Pfizer, Inc.
    8. Sanofi Pasteur
    9. Serum Institute of India
    10. Walvax Biotechnology
    11. Royal (Wuxi) Bio-Pharmaceutical
    12. Zhifei Biologic
  9. Market Outlook & Investment Opportunities
  10. Appendix
      1. List of Tables
      2. List of Figures
  • Global, regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped.
  • Segment-level analysis in terms of disease indication, type, patient stage and pathogen type along with market size forecasts and estimations to detect key areas of industry growth in detail.
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics.
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographics, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis.
  • Study the microenvironment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analyzing the level of competition and business strategy development.
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment.
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies.
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis, and main conclusions.
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market.
  1. Global Conjugate Vaccine Market, By Region, From 2021 to 2026 (USD Billion)
  2. Global Conjugate Vaccine Market, By Type, From 2021 to 2026 (USD Billion)
  3. Global Monovalent Conjugate Vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  4. Global Multivalent Conjugate Vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  5. Global Conjugate Vaccine Market, By Disease Indication, From 2021 to 2026 (USD Billion)
  6. Global Pneumococcal Market, By Region, From 2021 to 2026 (USD Billion)
  7. Global Influenza Market, By Region, From 2021 to 2026 (USD Billion)
  8. Global DTP Market, By Region, From 2021 to 2026 (USD Billion)
  9. Global Meningococcal Market, By Region, From 2021 to 2026 (USD Billion)
  10. Global Others Market, By Region, From 2021 to 2026 (USD Billion)
  11. Global Conjugate Vaccine Market, By Pathogen Type, From 2021 to 2026 (USD Billion)
  12. Global Bacterial Conjugate Vaccine Market, By Region, From 2021 to 2026 (USD Billion)
  13. Global Viral Conjugate Vaccine Market, By Region, From 2021 to 2026 (USD Billion)
  14. Global Combination (Viral and Bacterial) Conjugate Vaccine Market, By Region, From 2021 to 2026 (USD Billion)
  15. Global Conjugate Vaccine Market, By Patient Stage, From 2021 to 2026 (USD Billion)
  16. Global Pediatrics Conjugate Vaccine Market, By Region, From 2021 to 2026 (USD Billion)
  17. Global Adults Conjugate Vaccine Market, By Region, From 2021 to 2026 (USD Billion)
  18. North America Conjugate Vaccine Market, By Type, From 2021 to 2026 (USD Billion)
  19. North America Monovalent Conjugate Vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  20. North America Multivalent Conjugate Vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  21. North America Conjugate Vaccine Market, By Disease Indication, From 2021 to 2026 (USD Billion)
  22. North America Pneumococcal Market, By Region, From 2021 to 2026 (USD Billion)
  23. North America Influenza Market, By Region, From 2021 to 2026 (USD Billion)
  24. North America DTP Market, By Region, From 2021 to 2026 (USD Billion)
  25. North America Meningococcal Market, By Region, From 2021 to 2026 (USD Billion)
  26. North America Others Market, By Region, From 2021 to 2026 (USD Billion)
  27. North America Conjugate Vaccine Market, By Pathogen Type, From 2021 to 2026 (USD Billion)
  28. North America Bacterial Conjugate Vaccine Market, By Region, From 2021 to 2026 (USD Billion)
  29. North America Viral Conjugate Vaccine Market, By Region, From 2021 to 2026 (USD Billion)
  30. North America Combination (Viral and Bacterial) Conjugate Vaccine Market, By Region, From 2021 to 2026 (USD Billion)
  31. North America Conjugate Vaccine Market, By Patient Stage, From 2021 to 2026 (USD Billion)
  32. North America Pediatrics Conjugate Vaccine Market, By Region, From 2021 to 2026 (USD Billion)
  33. North America Adults Conjugate Vaccine Market, By Region, From 2021 to 2026 (USD Billion)
  34. United States Conjugate Vaccine Market, By Type, From 2021 to 2026 (USD Billion)
  35. United States Conjugate Vaccine Market, By Disease Indication, From 2021 to 2026 (USD Billion)
  36. United States Conjugate Vaccine Market, By Pathogen Type, From 2021 to 2026 (USD Billion)
  37. United States Conjugate Vaccine Market, By Patient Stage, From 2021 to 2026 (USD Billion)
  38. Canada Conjugate Vaccine Market, By Type, From 2021 to 2026 (USD Billion)
  39. Canada Conjugate Vaccine Market, By Disease Indication, From 2021 to 2026 (USD Billion)
  40. Canada Conjugate Vaccine Market, By Pathogen Type, From 2021 to 2026 (USD Billion)
  41. Canada Conjugate Vaccine Market, By Patient Stage, From 2021 to 2026 (USD Billion)
  42. Europe Conjugate Vaccine Market, By Type, From 2021 to 2026 (USD Billion)
  43. Europe Monovalent Conjugate Vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  44. Europe Multivalent Conjugate Vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  45. Europe Conjugate Vaccine Market, By Disease Indication, From 2021 to 2026 (USD Billion)
  46. Europe Pneumococcal Market, By Region, From 2021 to 2026 (USD Billion)
  47. Europe Influenza Market, By Region, From 2021 to 2026 (USD Billion)
  48. Europe DTP Market, By Region, From 2021 to 2026 (USD Billion)
  49. Europe Meningococcal Market, By Region, From 2021 to 2026 (USD Billion)
  50. Europe Others Market, By Region, From 2021 to 2026 (USD Billion)
  51. Europe Conjugate Vaccine Market, By Pathogen Type, From 2021 to 2026 (USD Billion)
  52. Europe Bacterial Conjugate Vaccine Market, By Region, From 2021 to 2026 (USD Billion)
  53. Europe Viral Conjugate Vaccine Market, By Region, From 2021 to 2026 (USD Billion)
  54. Europe Combination (Viral and Bacterial) Conjugate Vaccine Market, By Region, From 2021 to 2026 (USD Billion)
  55. Europe Conjugate Vaccine Market, By Patient Stage, From 2021 to 2026 (USD Billion)
  56. Europe Pediatrics Conjugate Vaccine Market, By Region, From 2021 to 2026 (USD Billion)
  57. Europe Adults Conjugate Vaccine Market, By Region, From 2021 to 2026 (USD Billion)
  58. U.K. Conjugate Vaccine Market, By Type, From 2021 to 2026 (USD Billion)
  59. U.K. Conjugate Vaccine Market, By Disease Indication, From 2021 to 2026 (USD Billion)
  60. U.K. Conjugate Vaccine Market, By Pathogen Type, From 2021 to 2026 (USD Billion)
  61. U.K. Conjugate Vaccine Market, By Patient Stage, From 2021 to 2026 (USD Billion)
  62. Germany Conjugate Vaccine Market, By Type, From 2021 to 2026 (USD Billion)
  63. Germany Conjugate Vaccine Market, By Disease Indication, From 2021 to 2026 (USD Billion)
  64. Germany Conjugate Vaccine Market, By Pathogen Type, From 2021 to 2026 (USD Billion)
  65. Germany Conjugate Vaccine Market, By Patient Stage, From 2021 to 2026 (USD Billion)
  66. France Conjugate Vaccine Market, By Type, From 2021 to 2026 (USD Billion)
  67. France Conjugate Vaccine Market, By Disease Indication, From 2021 to 2026 (USD Billion)
  68. France Conjugate Vaccine Market, By Pathogen Type, From 2021 to 2026 (USD Billion)
  69. France Conjugate Vaccine Market, By Patient Stage, From 2021 to 2026 (USD Billion)
  70. Italy Conjugate Vaccine Market, By Type, From 2021 to 2026 (USD Billion)
  71. Italy Conjugate Vaccine Market, By Disease Indication, From 2021 to 2026 (USD Billion)
  72. Italy Conjugate Vaccine Market, By Pathogen Type, From 2021 to 2026 (USD Billion)
  73. Italy Conjugate Vaccine Market, By Patient Stage, From 2021 to 2026 (USD Billion)
  74. Spain Conjugate Vaccine Market, By Type, From 2021 to 2026 (USD Billion)
  75. Spain Conjugate Vaccine Market, By Disease Indication, From 2021 to 2026 (USD Billion)
  76. Spain Conjugate Vaccine Market, By Pathogen Type, From 2021 to 2026 (USD Billion)
  77. Spain Conjugate Vaccine Market, By Patient Stage, From 2021 to 2026 (USD Billion)
  78. Asia Pacific Conjugate Vaccine Market, By Type, From 2021 to 2026 (USD Billion)
  79. Asia Pacific Monovalent Conjugate Vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  80. Asia Pacific Multivalent Conjugate Vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  81. Asia Pacific Conjugate Vaccine Market, By Disease Indication, From 2021 to 2026 (USD Billion)
  82. Asia Pacific Pneumococcal Market, By Region, From 2021 to 2026 (USD Billion)
  83. Asia Pacific Influenza Market, By Region, From 2021 to 2026 (USD Billion)
  84. Asia Pacific DTP Market, By Region, From 2021 to 2026 (USD Billion)
  85. Asia Pacific Meningococcal Market, By Region, From 2021 to 2026 (USD Billion)
  86. Asia Pacific Others Market, By Region, From 2021 to 2026 (USD Billion)
  87. Asia Pacific Conjugate Vaccine Market, By Pathogen Type, From 2021 to 2026 (USD Billion)
  88. Asia Pacific Bacterial Conjugate Vaccine Market, By Region, From 2021 to 2026 (USD Billion)
  89. Asia Pacific Viral Conjugate Vaccine Market, By Region, From 2021 to 2026 (USD Billion)
  90. Asia Pacific Combination (Viral and Bacterial) Conjugate Vaccine Market, By Region, From 2021 to 2026 (USD Billion)
  91. Asia Pacific Conjugate Vaccine Market, By Patient Stage, From 2021 to 2026 (USD Billion)
  92. Asia Pacific Pediatrics Conjugate Vaccine Market, By Region, From 2021 to 2026 (USD Billion)
  93. Asia Pacific Adults Conjugate Vaccine Market, By Region, From 2021 to 2026 (USD Billion)
  94. Japan Conjugate Vaccine Market, By Type, From 2021 to 2026 (USD Billion)
  95. Japan Conjugate Vaccine Market, By Disease Indication, From 2021 to 2026 (USD Billion)
  96. Japan Conjugate Vaccine Market, By Pathogen Type, From 2021 to 2026 (USD Billion)
  97. Japan Conjugate Vaccine Market, By Patient Stage, From 2021 to 2026 (USD Billion)
  98. China Conjugate Vaccine Market, By Type, From 2021 to 2026 (USD Billion)
  99. China Conjugate Vaccine Market, By Disease Indication, From 2021 to 2026 (USD Billion)
  100. China Conjugate Vaccine Market, By Pathogen Type, From 2021 to 2026 (USD Billion)
  101. China Conjugate Vaccine Market, By Patient Stage, From 2021 to 2026 (USD Billion)
  102. India Conjugate Vaccine Market, By Type, From 2021 to 2026 (USD Billion)
  103. India Conjugate Vaccine Market, By Disease Indication, From 2021 to 2026 (USD Billion)
  104. India Conjugate Vaccine Market, By Pathogen Type, From 2021 to 2026 (USD Billion)
  105. India Conjugate Vaccine Market, By Patient Stage, From 2021 to 2026 (USD Billion)
  106. Australia Conjugate Vaccine Market, By Type, From 2021 to 2026 (USD Billion)
  107. Australia Conjugate Vaccine Market, By Disease Indication, From 2021 to 2026 (USD Billion)
  108. Australia Conjugate Vaccine Market, By Pathogen Type, From 2021 to 2026 (USD Billion)
  109. Australia Conjugate Vaccine Market, By Patient Stage, From 2021 to 2026 (USD Billion)
  110. South Korea Conjugate Vaccine Market, By Type, From 2021 to 2026 (USD Billion)
  111. South Korea Conjugate Vaccine Market, By Disease Indication, From 2021 to 2026 (USD Billion)
  112. South Korea Conjugate Vaccine Market, By Pathogen Type, From 2021 to 2026 (USD Billion)
  113. South Korea Conjugate Vaccine Market, By Patient Stage, From 2021 to 2026 (USD Billion)
  114. Latin America Conjugate Vaccine Market, By Type, From 2021 to 2026 (USD Billion)
  115. Latin America Monovalent Conjugate Vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  116. Latin America Multivalent Conjugate Vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  117. Latin America Conjugate Vaccine Market, By Disease Indication, From 2021 to 2026 (USD Billion)
  118. Latin America Pneumococcal Market, By Region, From 2021 to 2026 (USD Billion)
  119. Latin America Influenza Market, By Region, From 2021 to 2026 (USD Billion)
  120. Latin America DTP Market, By Region, From 2021 to 2026 (USD Billion)
  121. Latin America Meningococcal Market, By Region, From 2021 to 2026 (USD Billion)
  122. Latin America Others Market, By Region, From 2021 to 2026 (USD Billion)
  123. Latin America Conjugate Vaccine Market, By Pathogen Type, From 2021 to 2026 (USD Billion)
  124. Latin America Bacterial Conjugate Vaccine Market, By Region, From 2021 to 2026 (USD Billion)
  125. Latin America Viral Conjugate Vaccine Market, By Region, From 2021 to 2026 (USD Billion)
  126. Latin America Combination (Viral and Bacterial) Conjugate Vaccine Market, By Region, From 2021 to 2026 (USD Billion)
  127. Latin America Conjugate Vaccine Market, By Patient Stage, From 2021 to 2026 (USD Billion)
  128. Latin America Pediatrics Conjugate Vaccine Market, By Region, From 2021 to 2026 (USD Billion)
  129. Latin America Adults Conjugate Vaccine Market, By Region, From 2021 to 2026 (USD Billion)
  130. Brazil Conjugate Vaccine Market, By Type, From 2021 to 2026 (USD Billion)
  131. Brazil Conjugate Vaccine Market, By Disease Indication, From 2021 to 2026 (USD Billion)
  132. Brazil Conjugate Vaccine Market, By Pathogen Type, From 2021 to 2026 (USD Billion)
  133. Brazil Conjugate Vaccine Market, By Patient Stage, From 2021 to 2026 (USD Billion)
  134. Argentina Conjugate Vaccine Market, By Type, From 2021 to 2026 (USD Billion)
  135. Argentina Conjugate Vaccine Market, By Disease Indication, From 2021 to 2026 (USD Billion)
  136. Argentina Conjugate Vaccine Market, By Pathogen Type, From 2021 to 2026 (USD Billion)
  137. Argentina Conjugate Vaccine Market, By Patient Stage, From 2021 to 2026 (USD Billion)
  138. Mexico Conjugate Vaccine Market, By Type, From 2021 to 2026 (USD Billion)
  139. Mexico Conjugate Vaccine Market, By Disease Indication, From 2021 to 2026 (USD Billion)
  140. Mexico Conjugate Vaccine Market, By Pathogen Type, From 2021 to 2026 (USD Billion)
  141. Mexico Conjugate Vaccine Market, By Patient Stage, From 2021 to 2026 (USD Billion)
  142. Rest of Latin America Conjugate Vaccine Market, By Type, From 2021 to 2026 (USD Billion)
  143. Rest of Latin America Conjugate Vaccine Market, By Disease Indication, From 2021 to 2026 (USD Billion)
  144. Rest of Latin America Conjugate Vaccine Market, By Pathogen Type, From 2021 to 2026 (USD Billion)
  145. Rest of Latin America Conjugate Vaccine Market, By Patient Stage, From 2021 to 2026 (USD Billion)
  146. Middle East and Africa Conjugate Vaccine Market, By Type, From 2021 to 2026 (USD Billion)
  147. Middle East and Africa Monovalent Conjugate Vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  148. Middle East and Africa Multivalent Conjugate Vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  149. Middle East and Africa Conjugate Vaccine Market, By Disease Indication, From 2021 to 2026 (USD Billion)
  150. Middle East and Africa Pneumococcal Market, By Region, From 2021 to 2026 (USD Billion)
  151. Middle East and Africa Influenza Market, By Region, From 2021 to 2026 (USD Billion)
  152. Middle East and Africa DTP Market, By Region, From 2021 to 2026 (USD Billion)
  153. Middle East and Africa Meningococcal Market, By Region, From 2021 to 2026 (USD Billion)
  154. Middle East and Africa Others Market, By Region, From 2021 to 2026 (USD Billion)
  155. Middle East and Africa Conjugate Vaccine Market, By Pathogen Type, From 2021 to 2026 (USD Billion)
  156. Middle East and Africa Bacterial Conjugate Vaccine Market, By Region, From 2021 to 2026 (USD Billion)
  157. Middle East and Africa Viral Conjugate Vaccine Market, By Region, From 2021 to 2026 (USD Billion)
  158. Middle East and Africa Combination (Viral and Bacterial) Conjugate Vaccine Market, By Region, From 2021 to 2026 (USD Billion)
  159. Middle East and Africa Conjugate Vaccine Market, By Patient Stage, From 2021 to 2026 (USD Billion)
  160. Middle East and Africa Pediatrics Conjugate Vaccine Market, By Region, From 2021 to 2026 (USD Billion)
  161. Middle East and Africa Adults Conjugate Vaccine Market, By Region, From 2021 to 2026 (USD Billion)
  162. Middle East Conjugate Vaccine Market, By Type, From 2021 to 2026 (USD Billion)
  163. Middle East Conjugate Vaccine Market, By Disease Indication, From 2021 to 2026 (USD Billion)
  164. Middle East Conjugate Vaccine Market, By Pathogen Type, From 2021 to 2026 (USD Billion)
  165. Middle East Conjugate Vaccine Market, By Patient Stage, From 2021 to 2026 (USD Billion)
  166. Africa Conjugate Vaccine Market, By Type, From 2021 to 2026 (USD Billion)
  167. Africa Conjugate Vaccine Market, By Disease Indication, From 2021 to 2026 (USD Billion)
  168. Africa Conjugate Vaccine Market, By Pathogen Type, From 2021 to 2026 (USD Billion)
  169. Africa Conjugate Vaccine Market, By Patient Stage, From 2021 to 2026 (USD Billion)

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 4250

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample